Sodium Restrictions May Only Benefit Patients at Low Risk of HF, With Justin Ezekowitz, MD скачать в хорошем качестве

Sodium Restrictions May Only Benefit Patients at Low Risk of HF, With Justin Ezekowitz, MD

A recent secondary analysis of the SODIUM-HF trial has indicated potential heterogeneity of treatment (HTE) effects from dietary sodium restriction across baseline risk quartiles of patients with or at risk of heart failure (HF). Restriction of dietary sodium is frequently recommended for patients with HF, despite a lack of data explicitly proving the impact of sodium restriction on patient-centered outcomes. SODIUM-HF compared usual care with sodium dietary restriction of less than 1500 mg/d in patients with HF. Ultimately, the trial was neutral for the primary endpoint of cardiovascular-related hospital admission, cardiovascular-related emergency department visits, or all-cause death. Now, in an interview with Justin Ezekowitz, MD, we discussed this secondary analysis and its implications for broad sodium-restriction recommendations. “The largest trial we’ve ever done in this area is, in fact, the SODIUM-HF trial, and it shows that it was neutral for a clinical outcome,” Ezekowitz told HCPLive. “If that is our benchmark for what we implement in clinical practice, then we shouldn’t make broad, sweeping recommendations for all patients now that we recognize that we don’t operate in a vacuum. We should really think about the next trials that need to be done.” Read the full article here: https://www.hcplive.com/view/sodium-r... Key Timestamps 00:00:01 Intro 00:00:10 Study overview 00:01:02 Comparing to SODIUM-HF 00:03:16 Should sodium restrictions still be standard? 00:04:43 QOL versus mortality 00:05:44 Including HTE in future trials #cardiology #heartfailure #dieting